Bristol Myers Squibb (NYSE: BMY) strengthens Camzyos growth case with positive adolescent SCOUT-HCM data
Read More Pharma Industry News Genetic stratification reframes HMNC Brain Health’s BH-200 Phase 2b data and revives precision psychiatry strategy at ACNP Find out how HMNC Brain Health’s Phase 2b BH-200 data at ACNP reframed clinical risk and revived precision psychiatry strategy in depression. bySoujanya RaviJanuary 19, 2026